Literature review of human papillomavirus vaccine acceptability among women over 26 years

This publication has 37 references indexed in Scilit:

• Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years
  Vaccine, 2009
• Genital Warts Among 18- to 59-Year-Olds in the United States, National Health and Nutrition Examination Survey, 1999–2004
  Sexually Transmitted Diseases, 2008
• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
  The Lancet, 2007
• Human papillomavirus (HPV) 16/18 l1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 18 months after vaccination in women up to age 55 years
  Journal of Clinical Oncology, 2007
• Chapter 6: Epidemiology and transmission dynamics of genital HPV infection
  Vaccine, 2006
• Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World
  Journal of Clinical Oncology, 2006
• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
  The Lancet Oncology, 2005
• Global Cancer Statistics, 2002
  CA: A Cancer Journal for Clinicians, 2005
• Recurrent Respiratory Papillomatosis
  The Laryngoscope, 2001
• Epidemiology of Genital Human Papillomavirus Infection
  The American Journal of Medicine, 1997